Brief: Bausch Health Companies - FDA Approves Cabtreo(Tm) Topical Gel For Treatment Of Acne Vulgaris In Patients Twelve Years Of Age And Older
20/10/2023 22:31
Oct 20 (Reuters) - Bausch Health Companies Inc BHC.TO :
* BAUSCH HEALTH COMPANIES - FDA APPROVES CABTREO(TM) TOPICAL
GEL
FOR TREATMENT OF ACNE VULGARIS IN PATIENTS TWELVE YEARS OF AGE
AND OLDER
* BAUSCH HEALTH COMPANIES INC - CABTREO IS EXPECTED TO BE
AVAILABLE TO PATIENTS IN Q1 2024
Source text for Eikon: ID:
Further company coverage: BHC.TO
Recent news on Bausch Health Companies
See all newsCanada Stocks: TSX heads for monthly gain as mining stocks rise, oil retreats
Canada's Bausch Health Q1 revenue rises
Canada's Bausch Health beats Q1 adjusted EPS estimates
Pfizer, Teva lose bid to disqualify ex-prosecutor in generic drug price‑fixing case
Canada Stocks: TSX subdued as healthcare, financials drag; energy gains